Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.60 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529371 | 1.00 | HCRTR2 (0.60) | HCRTR2RAF1BRAFHDAC6TLR9 | |
| SCHEMBL27179589 | 1.00 | HCRTR2 (0.60) | HCRTR2RAF1BRAFHDAC6TLR9 | |
| SCHEMBL29723610 | 1.00 | HCRTR2 (0.60) | HCRTR2RAF1BRAFHDAC6TLR9 | |
| SCHEMBL27180553 | 0.93 | HCRTR2 (0.62) | HCRTR2HDAC6 | |
| SCHEMBL24529508 | 0.93 | HCRTR2 (0.62) | HCRTR2HDAC6 | |
| SCHEMBL27180557 | 0.93 | HCRTR2 (0.62) | HCRTR2HDAC6 | |
| SCHEMBL24529581 | 0.89 | HCRTR2 (0.63) | HCRTR2RAF1BRAFHDAC6GRIN2B | |
| SCHEMBL29723574 | 0.89 | HCRTR2 (0.63) | HCRTR2RAF1BRAFHDAC6GRIN2B | |
| SCHEMBL27180551 | 0.89 | HCRTR2 (0.63) | HCRTR2RAF1BRAFHDAC6GRIN2B | |
| SCHEMBL27180548 | 0.89 | HCRTR2 (0.63) | HCRTR2RAF1BRAFHDAC6GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | claimed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HCRTR2 2/4885RAF1 4377/4885BRAF 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.